Cervantes
Life Science Partners

 Our Team

  1. Title 1
    Title 1

Laura Brege

Lee Rauch

Ms. Brege has over 25 years of executive management experience in the pharmaceutical, biotechnology and venture capital industries. Most recently, Ms. Brege was President & CEO of Nodality, Inc., a private company focused on innovative personalized medicine approaches in oncology, immunology and immuno-oncology.  Prior to joining Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a global oncology company, including Executive Vice President and Chief Operating Officer. While at Onyx, she led multiple functions, including commercialization, strategic planning, corporate development, technical operations and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm investing in early stage technology companies. Previously Ms. Brege was SVP, CFO at COR Therapeutics, helping build the company from an early stage R&D company through commercial launch of a successful cardiovascular product. Earlier she served as CFO at Flextronics, Inc. and Treasurer of The Cooper Companies.
 
Ms. Brege serves on the Board of Directors of Acadia Pharmaceuticals, Aratana Therapeutics, Dynavax Technologies, Portola Pharmaceuticals and Pacira Pharmaceuticals.  Ms. Brege also serves on the Board of CLSA, the California Life Sciences Association (CLSA) dedicated to advancing California's life sciences innovation ecosystem.
 
Ms. Brege earned her undergraduate degrees from Ohio University, Honors Tutorial College and her MBA degree from the University of Chicago. 
  
Lee Rauch has over 25 years of executive management and consulting experience in the pharmaceutical and biotechnology industries. Most recently, Ms. Rauch was Chief Business Officer of Global Blood Therapeutics (GBT), a Third Rock Venture biopharmaceutical start up that  completed its IPO in 2015. Prior to GBT, Ms. Rauch was President and CEO of Nuon Therapeutics, a private, clinical development stage company focused on inflammatory and rheumatic diseases. Ms. Rauch also held full time and interim senior-level positions at Onyx Pharmaceuticals, including Chief Business Officer and Vice President Corporate Development. Prior to Onyx, Ms. Rauch was SVP of Corporate Development at COR Therapeutics where she led the $2 billion sale of the company to Millennium Pharmaceuticals (now part of Takeda). Earlier in her career, she was VP of Strategic Marketing and New Product Planning for Syntex (acquired by Hoffmann-La Roche)
 
Ms. Rauch’s consulting experience includes heading the Life Science Practice as a partner at the Mitchell Madison Group (acquired by US Web), where she directed the global integration of Stryker with Pfizer’s Howmedica Division resulting in a $5.9 billion combined company.  Earlier in her career, she worked in the multinational pharmaceutical practice at McKinsey & Co.
 
Ms. Rauch earned her undergraduate degree in chemistry from Arizona State University and her MBA degree from the University of Chicago.

Therapeutic Areas

Industry Sectors

Marketed Products

  
Over 25 years experience as executives, company builders and investors in life sciences and emerging technologies
  
  
Oncology
Cardiovascular 
Asthma, allergy
Cough
Autoimmune diseases
CNS disorders
Orphan drugs
  
  
  
Biopharmaceuticals
Pharma
Antibodies
Diagnostics
Specialty pharma
  
  
  
Kyprolis
Nexavar
INTEGRILIN
Cellcept
Cytovene